#United States #New York #Securities Class Action #Faruqi & Faruqi #Aldeyra Therapeutics

Aldeyra Therapeutics Legal Notice: A Call for Action

Investors in Aldeyra Therapeutics, Inc. (ticker: ALDX) have been alerted by Faruqi & Faruqi, LLP, a prominent securities law firm, to the impending deadline of May 29, 2026, for filing in a federal securities class action against the company. This development comes amid serious allegations that the company's executives misled investors through false claims about their product’s clinical trial results, specifically the trial for reproxalap, a candidate aimed at treating dry eye disease.

Allegations Against Aldeyra

The law firm is probing potential claims against Aldeyra Therapeutics, focusing on allegations that the company violated federal securities laws. The suit derives from disclosures made on March 17, 2026, when Aldeyra announced that the FDA had rejected its New Drug Application (NDA) for reproxalap, citing a lack of sufficient evidence to demonstrate the drug's effectiveness. This rejection came after the agency identified significant inconsistencies in the results of the clinical trials, raising concerns about the viability of the drug and the company's prior assertions.

The complete response letter from the FDA highlighted that the clinical studies did not provide adequate and well-controlled support for the efficacy claims made by Aldeyra. Following this news, Aldeyra’s stock plummeted by 70.7%, diminishing from $4.23 to $1.24 per share in a single trading session. This dramatic fall underscores the potential financial impact on investors who purchased shares during the designated period from November 3, 2023, to March 16, 2026.

Taking Action: Class Representative Role

The lead plaintiff in a class action lawsuit typically represents the interests of all affected shareholders. Interested investors who suffered losses are encouraged to take action by either moving to serve as a lead plaintiff or remaining as part of the class. The lead plaintiff’s role involves directing the litigation while ensuring that the claims of all shareholders are adequately represented.

In essence, it is crucial for those who have been affected by the misrepresentations allegedly made by Aldeyra to understand their legal rights and options. Faruqi & Faruqi, LLP suggests that those with information regarding the company's conduct—whether whistleblowers, former employees, or shareholders—should come forward to assist in building a stronger case.

How to Proceed

Investors interested in learning more about the case or considering joining the class action are encouraged to visit Faruqi & Faruqi's website for detailed information. Furthermore, those wishing to speak directly to an attorney can contact partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310).

Conclusion

With the deadline for filings approaching, affected investors must stay informed about their rights and the ongoing developments in this case. The determination of the lead plaintiff and the outcome of this class action can significantly affect the recovery of losses for shareholders of Aldeyra Therapeutics. As the investigation unfolds, staying connected with legal updates will be key for investors navigating this tumultuous period.